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Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 39-unstranslated region of the DMPK gene, which encodes
a serine/threonine protein kinase. One of the common clinical features of DM1 patients is insulin resistance, which has been
associated with a pathogenic effect of the repeat expansions. Here we show that DMPK itself is a positive modulator of insulin
action. DMPK-deficient (dmpk2/2) mice exhibit impaired insulin signaling in muscle tissues but not in adipocytes and liver,
tissues in which DMPK is not expressed. Dmpk2/2 mice display metabolic derangements such as abnormal glucose tolerance,
reduced glucose uptake and impaired insulin-dependent GLUT4 trafficking in muscle. Using DMPK mutants, we show that
DMPK is required for a correct intracellular trafficking of insulin and IGF-1 receptors, providing a mechanism to explain the
molecular and metabolic phenotype of dmpk2/2 mice. Taken together, these findings indicate that reduced DMPK expression
may directly influence the onset of insulin-resistance in DM1 patients and point to dmpk as a new candidate gene for
susceptibility to type 2-diabetes.
Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, et al (2007) Role of Myotonic Dystrophy Protein Kinase (DMPK) in Glucose Homeostasis
and Muscle Insulin Action. PLoS ONE 2(11): e1134. doi:10.1371/journal.pone.0001134
INTRODUCTION
Type 2 diabetes is a heterogeneous disease and a major international
public health threat. It is widely accepted that type 2 diabetes results
from a combination of genetic susceptibility and other risk factors
including obesity, increased age, hypertension, and lifestyle [1].
Insulin resistance, which is a major factor in the development of type
2 diabetes [2], is a common metabolic feature in myotonic dystrophy
1 (DM1), an autosomal dominant neuromuscular disorder [3]. DM1
patients frequently exhibit normal basal insulin levels but excessive
insulin release after a glucose load, indicating a compensatory beta-
cell response to tissue insulin insensitivity [4,5]. Whole-body glucose
disposal in DM1 patients is reduced by 15225% following insulin
infusion [6] and experiments with forearm muscle indicate a 70%
decrease in insulin sensitivity in skeletal muscle [7]. The DM1
mutation has been identified as the expansion of an unstable CTG-
repeat in the 39-untranslated region of a gene encoding DMPK
(myotonic dystrophy protein kinase) [8,9]. Insulin resistance in DM1
has been associated with aberrant splicing of the insulin receptor
RNA due to a toxic effect of the CUG-expanded repeats, which are
transcribed from the mutated dmpk gene but are retained in the
nucleus altering the normal metabolism of RNAs [10,11]. However,
whether the entire endocrine pathology of DM1 is caused by
alterations in RNA processing remains to be seen. Indeed, DM1
patients show a 50% decrease in DMPK expression [12] and studies
of dmpk knockout mice indicate that at least some of the features of
DM1 result from haploinsufficiency of DMPK [13–15]. Interesting-
ly, dmpk gene is located on chromosome 19q13, in which quantitative
trait loci (QTLs) for type 2 diabetes-associated phenotypes have been
identified by two independent genome-wide linkage scans among
large and multiple ethnicity populations [16,17].
DMPK is mainly expressed in muscle [18], which is a key target
tissue for insulin-dependent regulation of glucose metabolism [19].
Structurally, DMPK presents homology with protein kinases of the
Rho family (Rho-kinase), which have important roles in the
organization of the cytoskeleton and several cellular processes
including intracellular protein trafficking and metabolism [20,21].
Although little is known about the mechanisms that regulate DMPK
activity, it has been described that DMPK is activated in response to
G protein second messengers [22] and that the actin cytoskeleton-
linked GTPase Rac-1 binds to DMPK, promoting its transpho-
sphorylation activity in a GTP-sensitive manner [23]. Here we
examined the role of DMPK in the regulation of insulin action and
glucose homeostasis using a DMPK-deficient mouse model [13]. We
show that DMPK plays a role in the regulation of whole-body glucose
disposal and muscle insulin sensitivity through a mechanism that
involves the intracellular trafficking of insulin and IGF-1 receptors.
RESULTS
Dmpk2/2 mice exhibit insulin signaling defects in
skeletal and cardiac muscles
We used dmpk–null mice to explore the involvement of DMPK in
insulin action. We first analyzed cardiac and skeletal muscles, in
which DMPK is preferentially expressed [18]. Dmpk2/2 mice
showed normal expression of the insulin receptor and other
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components of the insulin signaling pathway, such as the protein
kinase Akt and glycogen synthase kinase 3b (GSK3-b) (Fig. 1 A).
However, abnormalities were found in the activation of the insulin
signaling pathway in both cardiac and skeletal muscle. Insulin-
induced autophosphorylation of the insulin/IGF-I receptor
(Tyr1150/1151-InsR; Tyr1135/1136-IGF-1R) was substantially
decreased in dmpk2/2 mice after insulin treatment in vivo (54610%
decrease in cardiac muscle; 44610% decrease in skeletal muscle)
(Fig. 1 A). Phosphorylation of other components of the insulin
signaling pathway such as Ser473-Akt and Ser9-GSK3-b was also
Figure 1. DMPK regulates muscle insulin signaling. (A) Cardiac and skeletal muscles (soleus and gastrocnemius); (B) white adipose tissue; and (C)
liver homogenates from dmpk2/2 and wild type mice were analysed by Western blot. Caveolin 3, caveolin 1 and b-actin were used as loading
controls. Heart homogenate was loaded as positive control for DMPK expression in B and C. (D) C2C12 myoblasts transduced with recombinant
adenovirus for myc-DMPK or green fluorescent protein (GFP) as control were analyzed by Western blot. Caveolin 3 was used as loading control. Data
are means6SEM. *P,0.05 vs control values (n = 3-5).
doi:10.1371/journal.pone.0001134.g001
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severely reduced in cardiac muscle from dmpk2/2 mice (3965%
decrease in Akt phosphorylation; 6769% decrease in GSK3-
b phosphorylation) (Fig. 1 A). In contrast, insulin-induced autopho-
sphorylation of the insulin/IGF-I receptor and phosphorylation of
Ser473-Akt were preserved in adipose tissue and liver (Fig. 1 B and
C, respectively), in which DMPK is not expressed. These results
suggest that insulin signaling defects in dmpk2/2 mice are restricted
to DMPK-expressing tissues. A role of DMPK in muscle insulin
signaling was corroborated by overexpression of DMPK in C2C12
skeletal muscle cells. In myoblasts transduced with myc-tagged
wild-type DMPK-adenovirus, insulin-stimulated phosphorylation of
Ser473-Akt and Ser9-GSK3-bwas increased 1.860.2- and 5.562.6-
fold, respectively, compared to control cells (Fig. 1 D).
Metabolic alterations in dmpk2/2 mice
To examine whether dmpk2/2mice display muscle insulin resistance,
we first measured insulin-stimulated glucose transport in cardiac and
skeletal muscle. In myocytes isolated from left ventricles and soleus
muscles from dmpk2/2 mice, insulin-stimulated glucose transport
was decreased compared with wild-type mice (Fig. 2 A and C,
respectively). The alterations in glucose uptake were not due to
a decrease in the insulin receptor or the glucose transporter GLUT4
expression levels (Fig. 2 B and D). Moreover, expression of caveolin
3, a specific muscular marker of caveolae that is altered in other forms
of muscular dystrophies [24] and is required for insulin-stimulated
glucose uptake [25], was also normal in cardiac and skeletal muscles
from dmpk2/2mice. We further studied the role of DMPK in muscle
insulin sensitivity by analyzing GLUT4 translocation, a critical
muscle response to insulin. We performed subcellular fractionations
of cardiac muscle membranes from wild-type and dmpk2/2 mice.
Endosomes and sarcolemmal membrane fractions were separated by
successive spins of homogenates (Fig. 2 E). Low density microsome
(LDM) fractions were enriched in GLUT4 and contained very low
levels of Na+/K+-ATPase, indicating that such fractions were mostly
devoid of plasma membrane. In wild-type mice, GLUT4 content in
plasma membrane (PM) fraction was increased 51615% by insulin
injection, at the expense of the LDM pool of GLUT4, which showed
2364% reduction upon insulin treatment. Insulin-induced trans-
location of GLUT4 from LDM to PM was not detected in dmpk2/2
mice (Fig. 2 F).
Glucose tolerance tests performed at 4 weeks of age were
similar for dmpk2/2 and wild-type mice (Fig. 3 A). In contrast, at
8–10 weeks of age glucose tolerance in both male and female
dmpk2/2 mice was altered (Fig. 3 B and C, respectively). Plasma
insulin levels measured during glucose tolerance tests were also
elevated in dmpk2/2 as compared to wild-type mice (Fig. 3 D).
However, dmpk2/2 mice showed normal fasting glucose and
glycemia returned to baseline 2 h after glucose injection in both
groups. Fasted dmpk2/2 mice showed normal insulin, triglyceride
and free fatty acid levels (Table 1) while these parameters in fed
animals were higher than those from control animals (Fig. 3 E). No
increases in fat-cell mass or fat-cell number were detected in
dmpk2/2mice (Fig. 3 F). The glucose intolerant response of dmpk2/2
mice placed on a high-fat diet for 8 weeks was more severe than that
of dmpk2/2 mice on a standard chow diet. Indeed, this metabolic
stress significantly increased fasting blood glucose levels as well as
glycemia 2 h after the glucose overload in dmpk2/2 compared to
wild type mice (Fig. 3 G).
DMPK is required for insulin receptor targeting to
the plasma membrane
Regarding the molecular mechanism whereby DMPK activity
could influence insulin receptor signaling, previous observations
Figure 2. Decreased insulin-dependent glucose transport and
abnormal GLUT4 translocation in dmpk2/2 muscle. (A, C) Ex vivo
glucose uptake in myocytes isolated from left ventricles (n = 6 per
group) and soleus muscles (n = 3 per group), stimulated with or without
insulin (100 nM). (B, D) Insulin receptor, glucose transporter GLUT4,
caveolin 3 and DMPK protein contents were analyzed in cardiomyocytes
and soleus, respectively, from wild-type (WT) and dmpk2/2 (KO) mice
(n = 3). (E, F) Subcellular fractions were prepared from cardiac ventricles
of basal and insulin-treated mice. (E) Plasma membranes (PM) and low
density microsomes (LDM) were analysed by SDS-Page and Western
blot. Representative autoradiograms from 3 experiments are shown.
Equal amounts of membrane proteins (4 mg) from the different
fractions were laid on gels. (F) GLUT4 translocation was quantified
from 3 independent experiments. (Data are mean6SEM; *P,0.05 vs
unstimulated values)
doi:10.1371/journal.pone.0001134.g002
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led us to analyze the role of DMPK in stress fiber formation: (i)
DMPK function has been associated with the regulation of
cytoskeleton in lens cells [26], and (ii) it has recently been shown
that disruption of the actin cytoskeleton leads to alterations in
insulin receptor localization and signaling [27]. We used two
mutants of DMPK: myc-K110ADMPK, a kinase deficient form
mutated at the ATP-binding site [28], and myc-DMADMPK,
which lacks C-terminal residues 550-629 but retains kinase activity
[22]. HeLa cells were transiently transfected with wild-type myc-
DMPK, myc-K110ADMPK or myc-DMADMPK. Transfected
cells were analyzed after 3-h starvation to determine the stress
fiber content in steady state (Fig. 4 A and B). The stress fiber
pattern in cells expressing myc-WTDMPK was indistinguishable
from that of the surrounding untransfected cells (Fig. 4 A, a–c and
Figure 3. Metabolic parameters in dmpk2/2 mice. Glucose tolerance tests of (A) 4-week-old males; (B) 8–10-week-old males; (C) 8–10 week-old
females. (wild type , black squares; dmpk2/2mice, white circles). (n = 5–8 mice per group) (D) Plasma insulin, during glucose tolerance test performed
on 16 h-fasted mice (n = 528 for each group). (E) Insulin, triglycerides, and free fatty acids (FFAs) concentrations in plasma from fed mice (n = 8–14 for
each group). (F) Glucose tolerance tests on 4-month-old males on high fat diet (n = 8 per group; wild type, black squares; dmpk2/2 mice, white
circles). Data are mean6SEM; *P,0.05; **P,0.001; ***P,0.0001 vs wild-type values.
doi:10.1371/journal.pone.0001134.g003
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Fig. 4 B). Expression of the kinase-dead mutant myc-
K110ADMPK resulted in a disassembly of stress fibers (Fig. 4 A,
d–f and Fig. 4 B) while myc-DMADMPK induced a gross
condensation of actin filaments within the cell (Fig. 4 A, g–i and
Fig. 4 B). These results were consistent with those previously
reported for DMPK in lens cells and for the DMPK homolog
ROKa in HeLa cells [26,29]. Having verified the effect of DMPK
mutants in stress fiber formation in HeLa cells, we analyzed their
effect in the intracellular trafficking of the insulin receptor. HeLa
cells were transiently co-transfected with yellow fluorescent
protein-tagged InsR (YFP-InsR) along with myc-WTDMPK,
Table 1. Metabolic parameters in fasted dmpk2/2 mice.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dmpk +/+ dmpk 2/2
Weight (g) 1861 1762
Blood glucose (mg/dl) 53.336 4.84 54.6062.16
Plasma insulin (ng/ml) 0.3460.08 0.3760.09
Plasma triglycerides (mM) 0.8560.06 0.7960.05
Data are means6SEM, ( n = 8-20)
doi:10.1371/journal.pone.0001134.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Figure 4. Overexpression of DMPK mutants alters stress fiber formation in HeLa cells. (A) Stress fiber formation was analyzed by phalloidin
labeling. Cells were transfected with myc-WTDMPK (a–c), the kinase-dead myc-K110ADMPK mutant (d–f), and the C-terminal lacking myc-DMADMPK
mutant (g–i). Arrowheads indicate the transfected cells. Scale bar, 24 mm (applies to all panels). Representative images from 3 independent
experiments are shown. (B) Stress fiber formation was quantified using the Image J software as phalloidin intensity/cell area. Values for untransfected
cells were set as 100%. Means from three independent experiments with 20 cells analyzed per condition are shown. Data are mean6SEM;
***P,0.0001 vs unstransfected cells.
doi:10.1371/journal.pone.0001134.g004
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myc-K110ADMPK, myc-DMADMPK or empty vector as
control. Co-transfected cells were analyzed by confocal immuno-
fluorescence after 3-h starvation to determine the localization of
YFP-InsR in steady state. In cells expressing either empty vector or
myc-WTDMPK, YFP-InsRwas targeted to the cell surface (Fig. 5 A,
a–d and e–h, respectively). Quantification analysis showed that the
overexpression of myc-WTDMPK induced a significant increase in
the receptor density at the plasma membrane compared to control
cells (Fig. 5 B). In contrast, in the presence of either myc-
K110ADMPK or myc-DMADMPK mutants, YFP-InsR was
retained in intracellular structures (Fig. 5 A, i–l and m–p,
respectively), with no evident co-localization with the DMPK
mutants (Fig. 5 A, k and o). For both mutants, the percentages of
YFP-InsR at the plasma membrane were significantly decreased
compared to control cells (Fig. 5 B). To identify the intracellular
compartments in which the YFP-InsR was retained, HeLa cells were
transfected with the vector encoding this protein and myc-
WTDMPK or myc-K110ADMPK and subjected to staining with
anti-myc antibody and a series of markers for different organelles.
Co-localization studies revealed that in the presence of myc-
K110ADMPK, the intracellularly retained receptor partially coin-
cides with the Golgi matrix protein GM130 (Fig. 6). No evidence of
co-localization was detected with early endosomes (EEA1) or to
recycling endosomes (transferrin receptor) (not shown).
Figure 5. DMPK is required for insulin receptor targeting to the plasma membrane. (A) HeLa cells were transiently co-transfected with YFP-InsR
along with control empty vector (a–d), myc-WTDMPK (e–h), myc-K110ADMPK (i–l) or myc-DMADMPK (m–p). Shown are representative images of 3
independent experiments. Scale bar, 24 mm (applies to all panels). (B) Receptor percentage at the cell surface was quantified by using Image J
software. Means from three independent experiments with 20 cells analyzed per condition are shown. Data are mean6SEM ; **P,0.001; ***P,0.0001
vs unstransfected cells.
doi:10.1371/journal.pone.0001134.g005
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To further analyze DMPK role in insulin receptor trafficking,
we measured the insulin binding activity in cardiomyocytes
isolated from dmpk2/2 and wild type mice. 125I-insulin binding
assays were carried out at 12uC on cells from 16-h fasted mice to
analyze cell surface binding in the absence of internalization. Cells
from dmpk2/2 mice showed a 3668% (n= 4, p,0.05) decrease in
125I-insulin binding at 0.033 nM insulin concentration compared
to controls (Table 2). This decrease was associated with a reduced
number of receptors at the cell surface with no apparent changes
in receptor affinity for the ligand as the percentage of 125I-insulin
displacement at saturating unlabeled insulin concentrations was
similar in both groups (58613% and 6268% displacement for
wild type and dmpk2/2 mice, respectively). To better understand
the metabolic phenotype of dmpk2/2 mice, we also analyzed the
impact of DMPK in the IGF1-receptor intracellular trafficking.
The results obtained by co-transfection of GFP-tagged IGF-1
receptor along with myc-WTDMPK, myc-K110ADMPK, myc-
DMADMPK or empty vector as control were similar to those
obtained for the insulin receptor (Fig. 7 A and B).
DISCUSSION
In this study, we addressed the molecular and metabolic function
of DMPK, a poorly characterized serine/threonine protein kinase.
Consistent with the preferential expression of DMPK in muscle
tissues [18], we show that dmpk2/2 mice exhibit insulin signaling
defects in cardiac and skeletal muscle. Our data indicate that
dmpk2/2 mice present a significant degree of metabolic alteration,
reflected in elevated glucose levels in glucose tolerance tests and
increased circulating fed insulin and lipid levels. As observed in
DM1 patients [4], dmpk2/2 mice show higher concentrations of
plasma insulin than wild-type mice in the glucose tolerance tests.
These mice exhibit impaired glucose uptake and GLUT4
translocation indicating that decreased insulin sensitivity in muscle
could be at the basis of the observed metabolic alterations. Indeed,
dmpk2/2 mice show normal adiposity and insulin signaling in
adipose tissue and liver, in which DMPK is not expressed.
Insulin-induced autophosphorylation of insulin/IGF1-R in
response to insulin is influenced by the number of receptors at
the cell surface. Correct intracellular trafficking of the InsR is
critical for insulin sensitivity and it has been shown that mutations
in the InsR gene that impair the transport of the receptor to the
plasma membrane lead to type 2 diabetes in humans [30]. After
insulin binding, InsR is rapidly internalized and either sent to
lysosomes for degradation, or recycled to the plasma membrane
Figure 6. Effect of kinase-deficient mutant DMPK (myc-K110ADMPK) on YFP-InsR subcellular distribution. HeLa cells were transiently co-
transfected with YFP-InsR along with myc-WTDMPK (upper panels) or myc-K110ADMPK (lower panels). Cellular distribution of YFP-InsR partially
coincides with that of Golgi complex protein GM130 in cells expressing myc-K110ADMPK (panel h). Dashed circles in b and f show the magnified
areas. Scale bar, 24 mm. Representative images of 3 independent experiments are shown.
doi:10.1371/journal.pone.0001134.g006
Table 2. Insulin binding to isolated cardiomyocytes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[insulin] nM
% insulin bound/105 cells
dmpk +/+ dmpk 2/2
0.033 6.060.5 3.860.4*
1 2.460.5 1.460.3
Results expressed as % of 125I-insulin specifically
bound at the indicated insulin concentration.
*P,0.05 vs. WT (n = 4)
doi:10.1371/journal.pone.0001134.t002..
..
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for another round of binding, activation, and internalization [31].
Our results show that: (i) the insulin receptor expression levels in
dmpk2/2 mice are normal; (ii) the insulin binding to the plasma
membrane of dmpk2/2 cardiomyocytes is decreased; (iii) the
overexpression of kinase-deficient and C-terminal truncated
DMPK mutants leads to the retention of the InsR in intracellular
compartments; and (iv) the overexpression of wild-type myc-
DMPK increased the percentage of YFP-InsR at the cell surface.
Altogether, these data indicate that DMPK is involved in InsR
intracellular trafficking. However, this molecular mechanism
cannot fully explain the metabolic alterations observed in
dmpk2/2 mice, especially considering the previous characterization
of the muscle-insulin receptor knockout (MIRKO) mice which do
not show glucose intolerance [32]. For this reason, we analyzed
whether DMPK also regulated the targeting of IGF-1 receptor to
the plasma membrane. Indeed, functional inactivation of the IGF-
1 and insulin receptors in skeletal muscle (MKR mice) leads to
type 2 diabetes phenotype [33]. Interestingly, the glucose tolerance
tests performed in 4-week-old MKR mice are very similar to those
observed in 8–10-week-old dmpk2/2 animals. However, in contrast
to MKR mice, older dmpk2/2 mice do not develop type 2 diabetes.
The milder phenotype of dmpk2/2 mice compared to MKR mice
Figure 7. DMPK is required for IGF-1 receptor targeting to the plasma membrane. (A) HeLa cells were transiently co-transfected with GFP-IGF-1
along with control empty vector (a–d), myc-WTDMPK (e–h), myc-K110ADMPK (i–l), or myc-DMADMPK- (m–p). Dotted arrows in panel k and l show
a cell which only incorporated the GFP-IGF-1 plasmid, expressing the receptor at the plasma membrane. In the same panels, neighboring cells co-
expressing the receptor and myc-K110ADMPK are indicated by continuous arrows; in these cells, the accumulation of the receptor in intracellular
compartments is observed. Shown are representative images of 3 independent experiments. Scale bar, 24 mm (applies to all panels). (B) Receptor
percentage at the cell surface was quantified by using Image J software. Means from three independent experiments with 20 cells analyzed per
condition are shown. Data are mean6SEM; **P,0.001; ***P,0.0001 vs unstransfected cells.
doi:10.1371/journal.pone.0001134.g007
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is consistent with a mechanism involving a reduction of InsR and
IGF-1R function rather than full inactivation of these receptors.
We show that the kinase and C-terminal domains in DMPK are
positive and negative regulators, respectively, of the cytoskeleton
reorganization. Similar functions were previously found for
DMPK in lens cells [26] and for homologous domains in Rho
kinase a [29]. Both kinase and C-terminal domain mutants of
DMPK alter insulin and IGF-1 receptor targeting to the plasma
membrane and stress-fiber formation; however, whether these
effects are functionally related remains to be determined. One
possibility is that DMPK could be involved in the biogenesis of
Golgi-derived transport carriers through regulation of actin
cytoskeleton dynamics. Indeed, when actin dynamics is impaired
by a variety of actin toxins that depolymerize or stabilize actin
filaments, the Golgi complex shows significant structural changes
[34]. Interestingly, we detected that the receptor intracellular
accumulation caused by DMPK kinase-deficient mutant partially
co-localizes with the Golgi matrix protein GM130.
In summary, our study provides in vivo and in vitro evidence for
the role of DMPK in the regulation of insulin action and glucose
homeostasis. Taken together, these findings indicate that reduced
DMPK expression may directly influence the onset of insulin-
resistance in myotonic dystrophy 1 patients and suggest that
DMPK could represent a susceptibility gene to type 2-diabetes.
MATERIALS AND METHODS
Mouse experiments
All animal studies were performed in accordance with the
guidelines and under approval of the Institutional Review
Committee for the Animal Care and Use of the University of
Barcelona and by the animal welfare regulations of the University
of California, San Diego. The dmpk2/+ heterozygous mice on
129SV background were generated by Reddy et al. [13]. These
mice were mated to produce littermates that were homozygous for
intact DMPK allele (WT) and homozygous for the null DMPK
allele (KO). Except when indicated, 3-month-old male mice were
used in experiments shown. Mice were backcrossed for at least 9
times maintaining the animals as congenic in the colony. Female
mice were also analyzed in most of the studies presented with
similar results.
Physiological assays
The following measurements were performed on randomly fed or
on 16-h fasted animals when indicated. We measured blood
glucose levels on whole venous blood using an automatic glucose
monitor (One Touch Basic, Lifescan). Plasma insulin levels were
measured by ELISA, using rat insulin as a standard (Crystal
Chem). Free fatty acids and triglyceride levels were quantified
from plasma using kits from Wako (NEFA-C Ki and Triglyceride
L-Type, respectively). We performed glucose tolerance test on
16 h fasted mice injected intraperitoneally with D-glucose (2 g/kg
body weight, Sigma). For high-fat diet treatment, mice were
individually placed on a fat-adjusted diet (60 kcal% from fat,
Research Diets, Inc., New Brunswick, NJ) for 8 weeks.
Cardiomyocyte isolation and glucose uptake assays
Left ventricle myocytes from 3-month-old mice were prepared by
collagenase digestion as described previously [35] except that cells
were finally resuspended in D-glucose-free DMEM (Gibco)
supplemented with sodium pyruvate (0.22 mg/ml) and 0.2%
BSA. Cardiomyocyte suspensions at 10% cytocrit were incubated
with or without 100 nM insulin at 35uC for 30 min. The transport
assay was initiated by the addition of 2-deoxy-D-glucose (1 mM
final concentration, containing 0.5 mCi of 2-deoxy-D-[3H]glucose,
Amersham Pharmacia Biotech). Glucose uptake was terminated
after 20 min by transferring the cell suspension to microfuge tubes
and immediately centrifuged at 1006g for 30 s. Cell pellets were
washed 3 times in ice-cold 50 mM D-glucose in PBS. Background
activity was determined by measuring the transport in a solution
that contained 50 mM D-glucose. Cells were lysed with 1 ml of
ice-cold 0.1 N NaOH with 0.1% SDS and aliquots were taken for
determination of radioactivity and protein levels.
For skeletal muscle glucose uptake assays, mice were sacrificed
by cervical dislocation and soleus muscles were rapidly dissected.
Muscles were then allowed to recover for 15 min in flasks
containing 2 ml of incubation medium (D-glucose-free DMEM
(Gibco) supplemented with 0.22 mg/ml sodium pyruvate and
0.2% BSA), continuously oxygenated with 95% O2, 5% CO2 in
a shaking water bath (35uC). After recovery, glucose transport was
performed by adding 2-deoxy-D-[3H]glucose (1 mM, 1 mCi/ml)
and (14C)mannitol (19 mM, 0.3 mCi/ml) for 20 min and then,
muscles were frozen, weighed, and digested in 1 ml of 0.5 N
NaOH. Radioactivity was determined by liquid scintillation
counting for dual labels and the extracellular and intracellular
spaces were calculated as described [36].
Subcellular membrane fractionation
Separation of cardiac sarcolemmal and endosomal membranes
from mouse hearts was performed by differential centrifugation as
previously described [37]. Successive spins at 1006g, 5,0006g,
20,0006g, 50,0006g and 100,0006g were performed. Membranes
pelleting at 20,0006g [plasma membrane fraction, PM] were
enriched in the plasma membrane marker Na+/K+-ATPase. To
obtain a fraction containing the intracellular GLUT4 pool, the
20,000 g supernatant was centrifuged for 30 min at 50,0006g,
resulting in the separation of a high-density microsome fraction
[highly contaminated with plasma membranes] and a low-density
microsomes (LDM) fraction in the supernatant. This supernatant
was finally ultracentrifuged for 60 min at 100,0006g to obtain the
LDM pellet. Combining the quantitated signals from LDM and
PM fractions indicates that 8365% of Na+/K+ ATPase is found in
PM fraction, while 7762% of GLUT4 is in LDM (n= 3, p,0.05).
125I-insulin binding assays
Insulin binding in suspended cells was measured as described [38].
Human biosynthetic insulin was a kind gift from Eli Lilly Co.
(Indianapolis, IN). A14-125I-human insulin was purchased from
Perkin-Elmer (Boston, MA). Cells were exposed to a tracer
concentration of A14-125I-labeled human insulin and varying
concentrations of unlabeled human insulin for 4 hr at 12uC.
Reactions were terminated by layering duplicate aliquots of the
binding reaction over dibutyl phthalate in microcentrifuge tubes and
centrifuging at 14,0006g for 30 sec. The supernatant was aspirated
off and the radioactivity in cell pellets determined. Specific binding
was calculated by subtracting non-specific binding measured in the
presence of a large excess (1.67 mM) of unlabeled insulin.
Weight and DNA content of WAT
Perirenal, perigonadal and subcutaneous adipose tissues were
carefully dissected and weighed to determine the fat pad weight as
percentage of total body weight. To determine fat pad cell
number, perirenal adipose tissue was resected, weighed, and
immediately frozen in liquid nitrogen. About 50 mg of tissue were
homogenized, and genomic DNA was extracted using Quant-iT
PicoGreen (Invitrogen) as described by the manufacturer. DNA
was measured by fluorimetric method.
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Biochemical analyses
16-h fasted mice were injected intraperitoneally with D-glucose
(1 g/kg body weight) and 10 min later, with insulin (5 U/kg body
weight). After 10 min, heart, skeletal muscle, adipose tissue and
liver were rapidly extracted, freeze clamped in liquid nitrogen and
homogenized as described previously [28]. Control tissues from
untreated fasted mice were obtained in parallel. Immunoblotting
analyses were performed following standard procedures. Anti-
bodies to mouse DMPK were from Zymed Laboratories.
Antibodies to insulin receptor b-subunit, caveolin 3 and caveolin
1 were from BD Transduction Laboratories. All other antibodies
used were from Cell Signaling Technology. Immunoblots were
scanned and signals were quantified using HP Precisionscan Pro
and Syngene Gene Tools software. Shown are representative
immunoblot data from at least 3 independent experiments which
were quantified and expressed as the mean6SEM relative ratio of
phosphoprotein to total protein between untreated and insulin-
treated mice.
Gene transfer by adenovirus vectors Adenoviruses
expressing myc-tagged human DMPK were generated by
homologous recombination as described [28]. Subconfluent
C2C12 cells were infected for 2 h with 100 plaque-forming
units/cell of adenovirus vector encoding either myc-DMPK or
green fluorescent protein (GFP) before the addition of a suitable
volume of myogenic culture media (DMEM with 5% horse serum
and antibiotics). After 2 days, myotubes were treated with or
without 100 nM insulin for 30 min at 37uC, harvested, lysed and
analyzed by immunoblotting as described above.
Cell transfection and confocal microscopy For cell
transfection experiments, HeLa cells on coverslips were
transiently transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Plasmids used
were: myc-tagged wtDMPK and myc-tagged DMADMPK [22];
myc-tagged K110ADMPK [28]; yellow fluorescent protein-tagged
insulin receptor (YFP-InsR) [39]; and green fluorescent protein-
tagged IGF-1 receptor (GFP-IGF-1) [40]. Thirty-six hours after
transfection, cells were serum starved for 3 h, then washed in PBS,
fixed for 30 minutes in 4% w/v paraformaldehyde and processed
for immunofluorescence as described above. Antibodies used were
anti-myc rabbit polyclonal antibody (Upstate), anti-myc mAb
9E10 (ATCC), mAb anti-GM130 [Amersham Biosciences], anti-
mouse Cy5-conjugated IgG (Jackson), anti-rabbit Alexa Fluor 555
IgG (Molecular Probes) and anti-mouse Alexa Fluor 594 IgG
[Molecular Probes]. For staining of actin filaments, the coverslips
were incubated with phalloidin conjugated to Alexa Fluor 594
(Molecular Probes). Cells were examined using a Zeiss LSM510
confocal laser microscope with an oil immersion 636/NA1.3
objective. Micrographs shown are representative optical sections
imaged through the centre of the cell. At least 20 cells for each
condition of 3 independent experiments were examined and
subjected to quantification analyses using Image J software.
Statistical analysis
Data are presented as mean6standard error. Statistical analysis
was performed using a two-tailed unpaired t-test. Two-way
analysis of variance (ANOVA) was applied for multiple compar-
isons, followed by the Bonferroni post hoc test. Values of P,0.05
were considered as statistically significant.
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